ArticleJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG2021
Known and new facts on basal cell carcinoma.
Article in Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 48 citations in OpenAlex.
- Development and validation of an artificial intelligence model for basal cell carcinoma detection and section completeness assessment in Mohs micrographic surgery in an Asian cohort.JAAD international · 2026Article
- Clinical Patterns in Patients with Basal Cell Carcinoma: A 10-Year Single-Center Retrospective Study.Medicina (Kaunas, Lithuania) · 2026Observational
- Dermatology-Related Quality of Life Measured with the Dermatology Life Quality Index in Basal Cell Carcinoma and Other Non-Melanoma Skin Cancers: A Systematic Review and Exploratory Meta-Analysis.Journal of clinical medicine · 2026Review
- Article
- Localization of dendritic cells and T cells within the tumor microenvironment in different types of skin cancer.Histochemistry and cell biology · 2026Article
- Metastatic Basal Cell Carcinoma With Unusual Molecular Genetics Findings.Clinical case reports · 2026Article
- Matrix metalloproteinase expression in basal cell carcinoma, squamous carcinoma, and melanoma: diagnostic and prognostic potential.Frontiers in oncology · 2026Article
- Impact of UV Exposure and Incidence of Merkel Cell Carcinoma Between 1990 and 2018 in Austria.Cancers · 2025Article
- Article
- The Epidemiological and Histopathological Profiling of Basal Cell Carcinoma: Insights from a 4-Year Institutional Cohort in a Romanian Clinical County Hospital.Diagnostics (Basel, Switzerland) · 2025Article
- Aggressive Basal Cell Carcinoma With Rib Metastasis: An Uncommon Presentation of a Common Skin Cancer.Cureus · 2025Article
- A descriptive review of common dermatological diseases encountered by manual therapy providers.The Journal of the Canadian Chiropractic Association · 2025Article
- Overview of skin cancer types and prevalence rates across continents.Cancer pathogenesis and therapy · 2025Review
- Analysis of IL10 gene promoter haplotypes and changes in mRNA expression and soluble levels in patients with basal cell carcinoma.Archives of dermatological research · 2025Article
- Article
- A Successful Nodular Basal Cell Carcinoma Defect Closure On The Mid-Cheek Using Modified Mini Cheek Advancement Flap.Cancer management and research · 2025Article
- Immunotherapy for locally advanced and metastatic basal cell carcinoma: a narrative review.Translational cancer research · 2024Review
- Combining Phototherapy and Gold-Based Nanomaterials: A Breakthrough in Basal Cell Carcinoma Treatment.International journal of molecular sciences · 2024Review
- Anti-aging Strategies and Topical Delivery of Biopolymer-based Nanocarriers for Skin Cancer Treatment.Current aging science · 2024Review
- Advancements in skin cancer treatment: focus on photodynamic therapy: a review.American journal of cancer research · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Basal cell carcinoma (BCC) is the most common malignant tumor in light-skinned people and amounts to about 75 % of all cases of skin cancer. Increasing incidence rates have been reported for decades all over the world. The main risk factors include UV radiation, male sex, light skin type, advanced age, long-term immunosuppression, a positive individual or family history, and certain genodermatoses. BCC metastasizes only rarely, and its mortality is low, but it is associated with significant morbidity. Genetic mutations especially in the hedgehog pathway play an important role in BCC pathogenesis. Non-invasive procedures such as optical coherence tomography or confocal laser scan microscopy are increasingly utilized for diagnostics in addition to visual inspection and dermatoscopy, but only in exceptional cases can histological confirmation of the diagnosis be dispensed with. Various clinical and histological subtypes have been defined. Differentiating between BCC with high and low risk of recurrence has a significant influence on the choice of treatment. Most BCC can be treated effectively and safely with standard surgery, or in selected cases with topical treatment. Locally advanced and metastasized BCC must be treated with radiation or systemic therapy. Radiation is also an option for older patients with contraindications for surgery. The hedgehog inhibitors vismodegib and sonidegib are currently approved for systemic therapy of BCC in Europe. Approval for the PD1 inhibitor cemiplimab as second-line therapy is expected in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.